Dashboard
1
Poor Management Efficiency with a low ROCE of 9.89%
- The company has been able to generate a Return on Capital Employed (avg) of 9.89% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 18.75% and Operating profit at -38.17% over the last 5 years
4
Negative results in Sep 25
Stock DNA
Pharmaceuticals & Biotechnology
CNY 803 Million (Micro Cap)
60.00
NA
0.00%
-0.09
1.22%
0.60
Revenue and Profits:
Net Sales:
186 Million
(Quarterly Results - Mar 2026)
Net Profit:
7 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
49.65%
0%
49.65%
6 Months
41.65%
0%
41.65%
1 Year
55.76%
0%
55.76%
2 Years
0.47%
0%
0.47%
3 Years
-10.76%
0%
-10.76%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Zhejiang Realsun Chemical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
18.75%
EBIT Growth (5y)
-38.17%
EBIT to Interest (avg)
64.46
Debt to EBITDA (avg)
0.63
Net Debt to Equity (avg)
-0.13
Sales to Capital Employed (avg)
0.45
Tax Ratio
12.57%
Dividend Payout Ratio
75.09%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.89%
ROE (avg)
9.44%
Valuation key factors
Factor
Value
P/E Ratio
60
Industry P/E
Price to Book Value
0.75
EV to EBIT
162.45
EV to EBITDA
20.66
EV to Capital Employed
0.72
EV to Sales
1.31
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.44%
ROE (Latest)
1.24%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
186.30
187.50
-0.64%
Operating Profit (PBDIT) excl Other Income
8.30
14.30
-41.96%
Interest
0.00
0.00
Exceptional Items
-0.20
-0.40
50.00%
Consolidate Net Profit
7.10
2.70
162.96%
Operating Profit Margin (Excl OI)
44.60%
10.50%
3.41%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -0.64% vs 15.03% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 162.96% vs 156.25% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
692.80
631.90
9.64%
Operating Profit (PBDIT) excl Other Income
53.40
33.70
58.46%
Interest
0.40
0.50
-20.00%
Exceptional Items
-0.60
0.00
Consolidate Net Profit
16.40
15.40
6.49%
Operating Profit Margin (Excl OI)
14.60%
-1.40%
1.60%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 9.64% vs -4.39% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 6.49% vs -78.55% in Dec 2024
About Zhejiang Realsun Chemical Co., Ltd. 
Zhejiang Realsun Chemical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






